Zacks Research upgraded shares of CAMP4 Therapeutics (NASDAQ:CAMP – Free Report) from a strong sell rating to a hold rating in a research report sent to investors on Monday morning,Zacks.com reports.
Several other equities research analysts have also issued reports on the company. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 10th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Piper Sandler restated an “overweight” rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.56.
View Our Latest Report on CAMP4 Therapeutics
CAMP4 Therapeutics Trading Down 2.0%
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The firm had revenue of $1.78 million for the quarter. As a group, analysts predict that CAMP4 Therapeutics will post -0.66 EPS for the current year.
Insider Transactions at CAMP4 Therapeutics
In related news, Director Richard A. Young bought 16,378 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $1.65 per share, with a total value of $27,023.70. Following the completion of the transaction, the director directly owned 186,388 shares of the company’s stock, valued at $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 36,031 shares of company stock worth $59,451 over the last three months. 21.69% of the stock is owned by corporate insiders.
Institutional Trading of CAMP4 Therapeutics
Several large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. acquired a new position in CAMP4 Therapeutics during the 4th quarter worth $70,000. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics during the 4th quarter worth $86,000. OMERS ADMINISTRATION Corp bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $115,000. Finally, Goldman Sachs Group Inc. bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $115,000.
CAMP4 Therapeutics Company Profile
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Read More
- Five stocks we like better than CAMP4 Therapeutics
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
